The Latest Breaking News from DVA

DaVita is set to announce its fourth-quarter results next month, with analysts forecasting a double-digit growth in the company’s bottom-line figure.

Despite DaVita’s recent outperformance relative to its broader sector, Wall Street analysts remain cautious about the stock’s prospects.

While DaVita has outperformed the broader market over the past year, analysts on Wall Street are exercising caution regarding its future prospects.

DaVita is all set to release its third-quarter earnings this month, and analysts expect a single-digit profit dip.

This healthcare pick has outperformed the broader market in 2024, but is still priced at a discount.

Although DaVita has outperformed the Dow Jones Industrials Average, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

'Too many have paid a very dear price ... the ultimate sacrifice'

Federal departments can't be trusted to solve military suicides alone and the government must intervene to stop the "crisis", Royal Commissioners warn.

DaVita has surpassed the broader market over the past year, and Wall Street analysts are cautious about the stock’s prospects.

DaVita is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit increase.

The medical industry, pivotal in elevating the quality of human life, is poised to remain buoyed due to medical breakthroughs, advanced medical discoveries, and rising health consciousness among individuals. Given this backdrop, quality medical stocks McKesson Corporation (MCK), Qiagen N.V. (QGEN), and DaVita Inc. (DVA) could be solid portfolio additions…